SCHEDULE 13D/A: Lipella Pharmaceuticals CEO's Voting Control Shifts as Resale Registration Statement Becomes Effective

Jonathan H. Kaufman's beneficial ownership of Lipella Pharmaceuticals Inc. common stock remains at 16.2%, but his voting control over shares held by Spartan Capital Securities, LLC has terminated following the SEC's declaration of effectiveness for the company's Resale Registration Statement.

Summary

• Jonathan H. Kaufman, President, CEO, Secretary, Treasurer, and Chairman of Lipella Pharmaceuticals Inc., beneficially owns 212,289 shares of the company's common stock.
• This represents 16.2% of the 1,208,919 shares of Common Stock outstanding as of January 15, 2025.
• His beneficial ownership comprises 112,352 shares purchased with personal funds and 99,937 shares from fully vested stock options.
• This Amendment No. 9 updates a previous filing due to the SEC declaring Lipella's registration statement on Form S-3 (Resale Registration Statement) effective on January 15, 2025.
• A prior irrevocable proxy agreement between Mr. Kaufman and Spartan Capital Securities, LLC, which granted Mr. Kaufman voting power over 303,041 shares of Series C Voting Convertible Preferred Stock and up to 97,216 Common Stock purchase warrants held by Spartan, has terminated.
• This termination occurred because the Resale Registration Statement, which registered the reoffer and resale of such shares, became effective.

Sentiment

Score: 5

Explanation: The filing is largely procedural, updating a change in voting control that was contingent on an expected event (S-3 effectiveness). While the CEO loses direct voting control over a block of shares, his personal beneficial ownership remains substantial. The effectiveness of the S-3 can be seen as a positive for liquidity, but also introduces potential selling pressure from Spartan.

Positives

• The Resale Registration Statement for shares held by Spartan Capital Securities, LLC being declared effective by the SEC on January 15, 2025, provides liquidity for those shares.
• Jonathan H. Kaufman, as CEO and Chairman, maintains a significant beneficial ownership stake of 16.2% in Lipella Pharmaceuticals Inc., demonstrating alignment with shareholder interests.

Negatives

• Jonathan H. Kaufman's voting control over a significant block of shares (303,041 Preferred Stock convertible into Common Stock and up to 97,216 Warrant Shares) previously held by Spartan Capital Securities, LLC has terminated. This reduces his direct influence over those specific shares.

Risks

• The termination of the proxy agreement allows Spartan Capital Securities, LLC to exercise their own voting power and potentially sell their shares (303,041 Preferred Stock convertible into Common Stock and up to 97,216 Warrant Shares) now that the Resale Registration Statement is effective, which could lead to increased selling pressure on Lipella Pharmaceuticals Inc.'s common stock.

Future Outlook

The effectiveness of the Resale Registration Statement on Form S-3 allows Spartan Capital Securities, LLC to reoffer and resell the shares of Preferred Stock and Common Stock purchase warrants they hold, which could impact the company's stock liquidity and trading dynamics.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership structure and voting control for a publicly traded pharmaceutical company. It reflects the procedural steps following a private placement and subsequent registration of shares for resale, common in the lifecycle of small-cap companies raising capital.

Corporate Governance

Related Party Transactions

• An irrevocable proxy and power of attorney existed between Jonathan H. Kaufman (CEO and Chairman) and Spartan Capital Securities, LLC, related to shares acquired by Spartan in a private placement Offering. This arrangement, while now terminated, represents a past related party understanding concerning voting control over securities.

Stakeholder Impact

• **Shareholders:** The effectiveness of the Resale Registration Statement could lead to increased liquidity for the shares held by Spartan Capital Securities, LLC, but also potentially increased selling pressure if Spartan decides to divest its holdings. The shift in voting control from the CEO to Spartan for a significant block of shares could alter the balance of power among major shareholders.
• **Management (Jonathan H. Kaufman):** While his personal beneficial ownership remains strong, the termination of the proxy means he no longer has direct voting control over the shares held by Spartan, potentially reducing his overall influence on corporate decisions tied to those specific votes.

Next Steps

• Spartan Capital Securities, LLC may now reoffer and resell the 303,041 shares of Series C Voting Convertible Preferred Stock (convertible into Common Stock) and up to 97,216 Common Stock purchase warrants, as the Resale Registration Statement is effective.

Key Dates

Keywords

Lipella Pharmaceuticals Inc., Jonathan H. Kaufman, Schedule 13D, Beneficial Ownership, SEC Filing, Common Stock, Preferred Stock, Stock Options, Private Placement, Resale Registration Statement, Form S-3, Spartan Capital Securities, Proxy Agreement, Corporate Governance